AP

ARS Pharmaceuticals, Inc.

SPRY·NASDAQ

$9.07

+1.9%
HealthcareBiotechnology

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

At a Glance

Live Snapshot
Market Cap$900.68M
EPS-1.7400
P/E Ratio-5.21
Earnings Date08/12/2026

spry

Other Current Assets

Last Annual Value

6.19M

3-Year CAGR

83%

5-Year CAGR

%

10-Year CAGR

26%

AP

ARS Pharmaceuticals, Inc. Competitors Analysis of Other Current Assets

SPRY · NASDAQ
CompanyOther Current Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
6.19M
N/AN/AN/A 
1.24M
-33.7%N/A15.5%
SVRA logo
Savara Inc.
NASDAQ:SVRA
1.29M
66.2%-3.0%29.9%
28.41M
49.4%N/A44.3%
1.00M
71.9%-31.3%N/A
-2.43M
N/AN/AN/A
PROK logo
ProKidney Corp.
NASDAQ:PROK
9.54M
919.4%228.3%N/A
9.45M
4.8%N/AN/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
3.29M
N/AN/A22.6%
AP

ARS Pharmaceuticals, Inc. Fair Value Envelope

SPRY · NASDAQ

Our analysis suggests that SPRY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $9.07, this represents a potential HIDDEN relative to our calculated worth for ARS Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $9.07